| scholarly article | Q13442814 |
| P356 | DOI | 10.1086/510388 |
| P698 | PubMed publication ID | 17173218 |
| P50 | author | Kathleen A. Shutt | Q39920417 |
| Anton Y. Peleg | Q42220362 | ||
| David L Paterson | Q59993174 | ||
| P2093 | author name string | Kareem Abu-Elmagd | |
| Shahid Husain | |||
| Fernanda P Silveira | |||
| Amadeo Marcos | |||
| Ron Shapiro | |||
| Kenneth R McCurry | |||
| Jerry Tran | |||
| Eun J Kwak | |||
| Ngoc Thai | |||
| Magdaline Ndirangu | |||
| P2860 | cites work | Diagnosis and Treatment of Disease Caused by Nontuberculous Mycobacteria | Q22241907 |
| Campath-1H in intestinal and multivisceral transplantation: preliminary data | Q30694989 | ||
| Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study | Q33342242 | ||
| Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation | Q34201121 | ||
| Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath | Q34304820 | ||
| Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. | Q34455633 | ||
| Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy | Q34561556 | ||
| Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. | Q36349776 | ||
| Immunosuppression: evolution in practice and trends, 1994-2004. | Q36448818 | ||
| The impact of Campath 1H induction in adult liver allotransplantation | Q38514430 | ||
| Tolerogenic immunosuppression for organ transplantation | Q41116219 | ||
| Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction - long-term results | Q43834374 | ||
| Lymphoplasmacytic hyperplasia (possibly pre-PTLD) has varied expression and appearance in intestinal transplant recipients receiving Campath immunosuppression | Q44384180 | ||
| Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. | Q44461489 | ||
| American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation | Q44495127 | ||
| Reversal of acute cellular rejection after renal transplantation with Campath-1H. | Q44640328 | ||
| The value of bile replacement during external biliary drainage: an analysis of intestinal permeability, integrity, and microflora | Q44801496 | ||
| Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning | Q44826910 | ||
| Campath-1H in renal transplantation: The University of Wisconsin experience. | Q45092670 | ||
| Fungal infections in transplant recipients receiving alemtuzumab | Q46452887 | ||
| Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years. | Q46485560 | ||
| Campath-1H immunosuppressive therapy reduces incidence and intensity of acute rejection in intestinal and multivisceral transplantation | Q47863140 | ||
| Infectious Complications Associated with Alemtuzumab Use for Lymphoproliferative Disorders | Q57053368 | ||
| ??? | Q28376762 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | opportunistic infection | Q835718 |
| antibody | Q79460 | ||
| P304 | page(s) | 204-212 | |
| P577 | publication date | 2006-12-13 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody | |
| P478 | volume | 44 |
| Q43875918 | A model for diagnosis of pulmonary infections in solid-organ transplant recipients |
| Q40302250 | A retrospective study to describe the epidemiology and outcomes of opportunistic infections after abdominal organ transplantation |
| Q62667741 | Acute Cellular Rejection and Infection Rates in Alemtuzumab vs Traditional Induction Therapy Agents for Lung and Heart Transplantation: A Systematic Review and Meta-analysis |
| Q41022599 | Acute Rejection Rates and Graft Outcomes According to Induction Regimen among Recipients of Kidneys from Deceased Donors Treated with Tacrolimus and Mycophenolate |
| Q38544529 | Advances in pharmacotherapy to treat kidney transplant rejection |
| Q51318263 | Alemtuzumab (Campath-1H) therapy for refractory rejections in pediatric heart transplant recipients. |
| Q39513891 | Alemtuzumab as Antirejection Therapy: T Cell Repopulation and Cytokine Responsiveness |
| Q40217347 | Alemtuzumab dose adjusted for body weight is associated with earlier lymphocyte repletion and less infective episodes in the first year post renal transplantation - a retrospective study. |
| Q42205515 | Alemtuzumab in lung transplantation: an open-label, randomized, prospective single center study |
| Q61817428 | Alemtuzumab induction combined with reduced maintenance immunosuppression is associated with improved outcomes after lung transplantation: A single centre experience |
| Q43970258 | Alemtuzumab induction in deceased donor kidney transplantation |
| Q38506652 | Analysis of acute cellular rejection episodes in recipients of primary intestinal transplantation: a single center, 11-year experience |
| Q38206175 | Antibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options |
| Q40168823 | Are the Polyomaviruses BK and JC Associated with Opportunistic Infections, Graft-versus-Host Disease, or Worse Outcomes in Adult Patients Receiving Their First Allogeneic Stem Cell Transplantation with Low-Dose Alemtuzumab? |
| Q37296969 | BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants |
| Q42287261 | BK virus replication and nephropathy after alemtuzumab-induced kidney transplantation. |
| Q92420896 | Central Nervous System Cryptococcal Infections in Non-HIV Infected Patients |
| Q37859378 | Combination antifungal therapy for disseminated fusariosis in immunocompromised patients : a case report and literature review. |
| Q47338197 | Conjugation of Transforming Growth Factor Beta to Antigen-Loaded Poly(lactide-co-glycolide) Nanoparticles Enhances Efficiency of Antigen-Specific Tolerance. |
| Q37916814 | Controversies about induction therapy |
| Q37226750 | Cryptococcosis in solid organ transplant recipients: current state of the science |
| Q42272288 | Cryptococcosis in solid organ transplantation |
| Q37474014 | Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature |
| Q34390310 | Current concepts on cytomegalovirus infection after liver transplantation |
| Q26829789 | Current state of renal transplant immunosuppression: Present and future |
| Q52728252 | Cytomegalovirus infections in lung and hematopoietic cell transplant recipients in the Organ Transplant Infection Prevention and Detection Study: A multi-year, multicenter prospective cohort study. |
| Q39010415 | Disseminated Mycobacterium tuberculosis following renal transplant with alemtuzumab induction |
| Q39064002 | Disseminated cryptococcosis, invasive aspergillosis, and mucormycosis in a patient treated with alemtuzumab for chronic lymphocytic leukaemia |
| Q43894398 | Epidemiology and risk factors of infections after solid organ transplantation |
| Q91740932 | Epidemiology, Risk Factors, and Outcomes of Opportunistic Infections after Kidney Allograft Transplantation in the Era of Modern Immunosuppression: A Monocentric Cohort Study |
| Q45390361 | Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma |
| Q35032603 | Five-year outcomes with alemtuzumab induction after lung transplantation |
| Q40590036 | Herpesvirus Respiratory Infections in Immunocompromised Patients: Epidemiology, Management, and Outcomes. |
| Q40259107 | Human herpesviruses 6, 7 and 8 in solid organ transplant recipients |
| Q35801652 | Hyperexpansion of Functional Viral-Specific CD8+ T Cells in Lymphopenia-Associated MCMV Pneumonitis |
| Q60176850 | Immunosuppressive Treatment and Its Effect on the Occurrence of Pneumocystis jiroveci, Mycoplasma pneumoniae, Chlamydophila pnemoniae, and Legionella pneumophila Infections/Colonizations Among Lung Transplant Recipients |
| Q37652611 | Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients. |
| Q41139700 | Impact of human herpes virus 6 in liver transplantation |
| Q34189873 | Importance of nonenteric protozoan infections in immunocompromised people. |
| Q39245827 | In vivo reprogramming of immune cells: Technologies for induction of antigen-specific tolerance. |
| Q38258154 | Induction therapy in renal transplant recipients: a review |
| Q37912944 | Infections associated with monoclonal antibody and fusion protein therapy in humans |
| Q37794618 | Infections due to human herpesvirus 6 in solid organ transplant recipients |
| Q38006195 | Infections in solid organ transplantation in special situations: HIV-infection and immigration |
| Q38944786 | Infectious Complications of Novel Multiple Sclerosis Therapies |
| Q37156636 | Infectious complications associated with monoclonal antibodies and related small molecules |
| Q39264020 | Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors. |
| Q42223053 | Kinetics of peripheral blood lymphocyte subpopulations predicts the occurrence of opportunistic infection after kidney transplantation |
| Q38149379 | Life-threatening infection in transplant recipients |
| Q33845124 | Management of cytomegalovirus infection and disease in liver transplant recipients. |
| Q36724093 | Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines |
| Q26826880 | Monoclonal antibody therapy and renal transplantation: focus on adverse effects |
| Q43194264 | Mycobacterium haemophilum infection after alemtuzumab treatment. |
| Q41991070 | Neurological complications of solid organ transplantation |
| Q37756120 | New developments in the management of cytomegalovirus infection after solid organ transplantation |
| Q84784155 | New immunosuppressive agents and risk for invasive fungal infections |
| Q38102315 | New perspectives of immunosuppression. |
| Q42844002 | Nocardiosis in a renal transplant recipient following rituximab preconditioning |
| Q99402278 | Opportunistic Infections After Induction With Alemtuzumab or Basiliximab: A 3-Year Kidney Transplantation Experience |
| Q38558078 | Opportunistic infections complicating solid organ transplantation with alemtuzumab induction |
| Q34112623 | Primary eosinophilic disorders: a concise review |
| Q37056103 | Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant |
| Q84784151 | Prophylaxis of invasive mycoses in solid organ transplantation |
| Q40295328 | Pulmonary Nocardia beijingensis infection associated with the use of alemtuzumab in a patient with multiple sclerosis |
| Q42205422 | Rapidly growing non-tuberculous mycobacterial infection in a renal transplant patient after alemtuzumab induction. |
| Q40167213 | Reactivation of Multiple Infectious Pathogens after Hematopoietic Stem Cell Transplantation |
| Q42907634 | Renal Failure Five Years After Lung Transplantation Due to Polyomavirus BK‐Associated Nephropathy |
| Q39409394 | Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation. |
| Q64098085 | Risks and risk management in modern multiple sclerosis immunotherapeutic treatment |
| Q82383996 | Screening of Deceased Organ Donors: No Easy Answers |
| Q26864234 | Selection of induction therapy in kidney transplantation |
| Q40056573 | Serotherapy with thymoglobulin and alemtuzumab differentially influences frequency and function of natural killer cells after allogeneic stem cell transplantation |
| Q37403242 | T10B9 monoclonal antibody: a short-acting nonstimulating monoclonal antibody that spares gammadelta T-cells and treats and prevents cellular rejection |
| Q27485255 | Transmission of Tropical and Geographically Restricted Infections during Solid-Organ Transplantation |
| Q43079825 | Treatment of simultaneous acute antibody-mediated rejection and acute cellular rejection with alemtuzumab in kidney transplantation: a case report |
| Q37715187 | Updated principles and clinical caveats in the management of infection in renal transplant recipients |
| Q62667736 | WITHDRAWN: Acute Cellular Rejection and Infection Rates in Alemtuzumab vs Traditional Induction Therapy Agents for Lung and Heart Transplantation: A Systematic Review and Meta-analysis |
| Q42148730 | What are fungal infections? |
| Q84028073 | [Prophylaxis of cytomegalovirus infection in intestinal transplantation] |
| Q84028040 | [Risk factors for cytomegalovirus in solid organ transplant recipients] |
Search more.